Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type
复制标题
DOI：
10.1093/annonc/mdf002
复制
发表时间：
2002-01-01
影响因子：
50.5
通讯作者：
Machin, D
中科院分区：
文献类型：
--
作者：
Foo, KF;Tan, EH;Machin, D
背景资料：我们进行了两个平行的11期临床试验，在化疗和以前治疗过的转移性鼻咽癌（NPC）患者中评估吉西他滨的肿瘤反应、无进展生存期和总生存期以及毒性。患者和方法：吉西他滨1250 mg/m2在21天周期的第1天和第8天给药。具有美国东部肿瘤协作组体能状态的患者
Background: We conducted two parallel phase 11 trials in chemonaive and previously treated patients with metastatic nasopharyngeal carcinoma (NPC) to evaluate the tumour response, progression-free and overall survival, and toxicity of gemcitabine.Patients and methods: Gemcitabine 1250 mg/m(2) was given on days 1 and 8 of a 21-day cycle. Patients with an Eastern Cooperative Oncology Group performance status